Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1349.20% is 106% below its 1-year average of 22853.33%, near the low end of its 1-year range (-1349.20%–45987.67%).
105.90% below its 12-month average of 22853.33%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2018 (2018-12-31): 45987.67%.
EBITDA MARGIN
-1349.20%
EBITDA MARGIN AVG TTM
22853.33%
EBITDA MARGIN AVG 3Y
22853.33%
EBITDA MARGIN AVG 5Y
22853.33%
EBITDA MARGIN AVG 10Y
15054.52%
EBITDA MARGIN AVG 15Y
634.31%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-105.90%
CURRENT VS 3Y AVG
-105.90%
CURRENT VS 5Y AVG
-105.90%
CURRENT VS 10Y AVG
-108.96%
CURRENT VS 15Y AVG
-312.70%
CURRENT VS 20Y AVG
N/A
DiaMedica Therapeutics Inc.
Market Cap
$453.70M
EBITDA Margin
-1349.20%
TTM Avg
22853.33%
3Y Avg
22853.33%
5Y Avg
22853.33%
Market Cap
$450.64M
EBITDA Margin
-16.58%
TTM Avg
-87.69%
3Y Avg
-357.20%
5Y Avg
-653.36%
Market Cap
$447.43M
EBITDA Margin
-184.73%
TTM Avg
-138.06%
3Y Avg
-2467.18%
5Y Avg
-2497.88%
Market Cap
$471.57M
EBITDA Margin
-3.52%
TTM Avg
-5.19%
3Y Avg
-11.78%
5Y Avg
-23.46%
Market Cap
$478.54M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
Market Cap
$428.16M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$481.33M
EBITDA Margin
-41.77%
TTM Avg
-67.13%
3Y Avg
-207.81%
5Y Avg
-270.93%
Market Cap
$487.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $453.70M | -1349.20% | 22853.33% | 22853.33% | 22853.33% |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | -16.58% | -87.69% | -357.20% | -653.36% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | -184.73% | -138.06% | -2467.18% | -2497.88% |
| NRC Health (NRC)vs › | $468.31M | 21.99% | 25.40% | 28.98% | 31.97% |
| Cerus Corporation (CERS)vs › | $471.57M | -3.52% | -5.19% | -11.78% | -23.46% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -31.76% | -31.76% | -31.76% | -31.76% |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | -232.13% | -495.69% | -578.57% | -532.48% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | -41.77% | -67.13% | -207.81% | -270.93% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | -107.01% | -86.79% | -53.66% | -431.14% |
Gross Margin
0.0%
EBITDA Margin
-1349.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2018-12-31 | 45987.67% |
| 2018-09-30 | -281.01% |
| 2008-12-31 | -543.09% |
| 2008-09-30 | 3567.99% |
| 2008-06-30 | 2633.98% |
| 2008-03-31 | 1402.51% |
| 2007-12-31 | 1702.69% |
| 2007-09-30 | 775.05% |
| 2007-03-31 | -2580.69% |
| 2006-09-30 | 6599.91% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 100.00% |
| 2005-03-31 | 100.00% |
